CompletedNCT00119652
Quetiapine or an SSRI for depression in bipolarity
Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Phoenix and 54 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 676
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, Chile, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00119652
- Official title
Show the full official title
Multicentre, Double-blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix, United States · Little Rock, United States · National City, United States
53 more locations
- San Clemente, United States
- San Diego, United States
- Maitland, United States
- Winter Park, United States
- Atlanta, United States
- Smyrna, United States
- Northfield, United States
- Oak Brook, United States
- New Orleans, United States
- Shreveport, United States
- Glen Burnie, United States
- St Louis, United States
- Clementon, United States
- New York, United States
- Raleigh, United States
- Cincinnati, United States
- Dayton, United States
- Oklahoma City, United States
- Philadelphia, United States
- Austin, United States
- Dallas, United States
- Irving, United States
- Richmond, United States
- Bellevue, United States
- Kirkland, United States
- Brisbane, Australia
- Everton Park, Australia
- Southport, Australia
- Epping, Australia
- Malvern, Australia
- Providencia Santiago, Chile
- Santiago, Chile
- Bogotá, Colombia
- San José, Costa Rica
- Athens, Greece
- Thessaloniki, Greece
- Tripoli, Greece
- México, Mexico
- Yucatán, Mexico
- Lima, Peru
- San Borja, Peru
- Bucharest, Romania
- Galati, Romania
- Iași, Romania
- Măgura, Romania
- Benoni, South Africa
- Cape Town, South Africa
- Durban, South Africa
- Pretoria, South Africa
- Gaziantep, Türkiye
- Istanbul, Türkiye
- Manisa, Türkiye
- Türkiye
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including quetiapine fumarate (Seroquel) and paroxetine.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
